Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Hartog

Allergy & Immunology Grand Rapids, MI Medical Doctor

NPI 1669766325 CMS profile 496381

3271 Clear Vista Ct Ne, Grand Rapids, MI 49525

Open in the dashboard

General payments

$575,153

791 records reported · program years 2019–2025

Research payments

$2,763

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,175 paid to institutions, not to them · program year 2023

Through program year 2025, Nicholas Hartog of Grand Rapids, MI is reported in the CMS Open Payments database as having received $575,153 across 791 general payments and $2,763 in research payments paid to them. Separately, studies naming them as principal investigator received $6,175 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $97,648 174
2024 General $179,690 202
2023 General $108,219 189
2022 General $87,114 101
2022 Research $2,763 1
2021 General $36,397 37
2020 General $29,773 26
2019 General $36,311 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Hartog
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Nicholas Hartog were reported at $97,648. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Nicholas Hartog Allergy & Immunology median Middle half National median
2019 $36,311 $594 $163–$1,512 $163
2020 $29,773 $426 $106–$1,233 $114
2021 $36,397 $638 $157–$1,708 $132
2022 $87,114 $790 $205–$1,961 $149
2023 $108,219 $852 $220–$2,147 $160
2024 $179,690 $865 $203–$2,267 $164
2025 $97,648 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pharming Healthcare, Inc. $165,748 247 payments
  2. Horizon Therapeutics plc $151,865 150 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $131,240 179 payments
  4. Amgen Inc. $80,288 81 payments
  5. Chiesi USA, Inc. $12,834 4 payments
  6. ADMA BioManufacturing LLC $8,537 10 payments
  7. Shire North American Group Inc $8,523 13 payments
  8. X4 Pharmaceuticals, Inc. $5,221 4 payments
  9. The Binding Site Inc. $3,705 3 payments
  10. Regeneron Healthcare Solutions, Inc. $2,437 15 payments
  11. Other $4,755 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $190,169 52 payments
  2. Honoraria $181,186 107 payments
  3. Consulting Fee $137,831 49 payments
  4. Travel and Lodging $53,450 266 payments
  5. Food and Beverage $12,351 314 payments
  6. Education $166 3 payments
Products named General payments · program years 2019–2025
  1. ACTIMMUNE Actimmune $151,761 146 payments
  2. JOENJA $125,640 181 payments
  3. ACTIMMUNE Bone/Inflammation/Rare Disease $56,836 52 payments
  4. CUVITRU $48,460 81 payments
  5. HYQVIA $27,574 33 payments
  6. REVCOVI $9,020 3 payments
  7. XOLREMDI $5,221 4 payments
  8. FREELITE $3,705 3 payments
  9. DUPIXENT $2,343 12 payments
  10. Xolair $1,848 5 payments
  11. Other $3,777 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pharming Healthcare, Inc. $2,763 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

263

Median for Allergy/ Immunology: 449

Drug cost

$1,575,880

Median for Allergy/ Immunology: $169,700

Branded share of claims

43.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Actimmune Interferon Gamma-1b,recomb. Brand 11 $1,459,113
Dupixent Syringe Dupilumab Brand 21 $74,559
Xolair Omalizumab Brand 11 $28,544
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $8,225
Albuterol Sulfate Hfa Albuterol Sulfate Brand 28 $1,545
Azelastine Hcl Generic 27 $984
Ipratropium Bromide Generic 18 $744
Montelukast Sodium Generic 51 $709
Fluticasone Propionate Generic 24 $440
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $351

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$8,965

Medicare's payments for the services billed

Medicare patients

59

Average age 62

Services billed

214

39 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 51%
Depression 42%
COPD 41%
Osteoporosis 27%
Diabetes 25%
Ischemic heart disease 20%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JOENJA
$54,541 — —
ACTIMMUNE
$43,798 11 —
HYQVIA
$9,378 — —
DUPIXENT
$279 21 —
TEZSPIRE
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

792 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record